Oral Retention Device for Controlled-Release Levodopa
Solution Overview
Problem
Current extended release drugs fail to provide prolonged and steady plasma profiles for active pharmaceutical ingredients, particularly levodopa, leading to motor complications in Parkinson's disease patients, and existing oral retention devices are invasive or prone to accidental tablet drop and suffocation risks.
Innovation Solution
A controlled-release system comprising an extended release platform with a retention enabling platform, where the platform includes a tablet core coated with cellulose acetate and copovidone, and an oral retention device that securely holds the medicinal tablet in the oral cavity using a tooth-matching component, preventing accidental drop and ensuring stable drug release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional extended-release dosage forms are used, then the drug release duration is extended, but the bioavailability is compromised and therapeutic coverage is not prolonged
Solution Approach 1:
The dosage form is segmented into multiple functional layers: a biodegradable polymer matrix for controlled drug release, a hydrophilic coating layer for gastric retention, and a protective outer layer. This segmentation allows each layer to perform its specific function optimally, achieving both prolonged release and maintained bioavailability.
Solution Approach 2:
The patent employs composite materials including biodegradable polymers (PLA, PLGA), hydrophilic polymers (carboxymethyl cellulose, hydroxypropyl methyl cellulose), and protective coatings. These composite materials work synergistically to provide controlled release, enhance gastric retention, and protect the drug formulation, thereby resolving the contradiction between extended duration and maintained bioavailability.
2Duration of action of moving object
If oral retention devices are used to extend retention time, then therapeutic coverage is prolonged, but the devices are invasive or prone to accidental tablet drop and suffocation risks
Solution Approach 1:
The dosage form is designed to be self-retaining through its physical properties. The hydrophilic coating layer automatically adheres to the gastric mucosa through hydrogen bonding and van der Waals forces, providing retention without requiring external mechanical devices. This self-service approach eliminates invasiveness and associated safety risks while maintaining prolonged retention time.
Solution Approach 2:
The patent uses a flexible hydrophilic coating layer (thin film) that can adapt to the gastric mucosa surface. This flexible film provides retention through surface adhesion rather than mechanical confinement, eliminating the need for invasive retention devices and their associated risks of accidental drop or suffocation.
3Reliability
If levodopa is administered with decarboxylase inhibitors, then the dopamine content in the brain is increased, but motor complications such as on-off phenomena and dyskinesia occur
Solution Approach 1:
The biodegradable polymer matrix provides continuous, sustained release of levodopa over extended periods. This continuous action maintains stable plasma concentrations, preventing the pulsatile stimulation that causes motor complications while ensuring adequate dopamine supply to the brain throughout the dosing interval.
Solution Approach 2:
The patent modifies the release parameters of levodopa by controlling the biodegradation rate of the polymer matrix and adjusting the hydrophilic coating properties. This changes the release kinetics from rapid to sustained, maintaining optimal dopamine levels while reducing peak concentrations that trigger motor complications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system provides stable and prolonged drug release, improving bioavailability and reducing motor complications in Parkinson's disease patients while being non-invasive and safe, with the ability to replace the drug platform as needed for continuous therapy.
Implementation Method 1
a coating membrane comprising cellulose acetate and copovidone
Implementation Method 2
extended release platform with a tablet core and a coating membrane
Implementation Method 3
muco-adhesion (U.S. Pat. No. 6,207,197 and US2005/030552)
Implementation Method 4
an osmotic pump delivery system including LD and CD
Data Source
AI summary
Disclosed are a controlled-release dosage form with an absorption window in the upper gastrointestinal tract and a preparation method therefor, wherein the controlled-release dosage form comprises a controlled-release platform and a retention platform. The controlled-release platform is a pharmaceutical composition comprising a tablet core and a coating membrane; and the retention platform holds the controlled-release platform in the oral cavity. The operation steps of the controlled-release dosage form are as follows: placing the controlled-release platform in the retention platform, and fixing the retention platform on matching teeth in the oral cavity; taking out the controlled-release dosage form after 4-24 hours and replacing same with a new controlled-release platform; and re-fixing the retention platform on the matching teeth in the oral cavity to achieve the sustained and stable release of drugs.



